Exploration on the immunogenic gene mutation in human glioblastoma mutiforme by the next generation sequencer for establishment of therapeutic vaccine

Exploration on the immunogenic gene mutation in human glioblastoma mutiforme by the next generation sequencer for establishment of therapeutic vaccine - Exploration on immunogenic gene mutation in human glioblastoma multiforme

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023546

Enrollment

Registered

2016-08-09

Start date

2015-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma multiforme

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Glioblastoma multiforme patients treated with dendritic/tumor cell fusion vaccine for prevention of recurrence whose tumor cells are stored for next generation sequencer analyses.

Exclusion criteria

Exclusion criteria: Glioblastoma multiforme patients treated with dendritic/tumor cell fusion vaccine for prevention of recurrence whose tumor cells are not stored for next generation sequencer analyses.

Design outcomes

Primary

Measure	Time frame
Amino acid sequence of the mutated anigen commonly expressed in long survovors treated with the dendritic cell vaccine will be determined. Peptide vaccine will be designed based on the structure of the mutated antigen.	—

Countries

Japan

Contacts

Public ContactYuko Kamata

Jikei University School of Medicine Division of Oncology

ykama@jikei.ac.jp03-3433-1111

Outcome results